Tech company files patent for AI software that makes gadolinium-free imaging possible

Michael Walter | | Radiology Business | Practice Management

IQ-AI, the healthcare technology and software holding company formerly known as Flying Brands, announced it has filed a patent for MR imaging that does not use gadolinium-based contrast agents (GBCAs). According to the company, the product was designed using deep learning techniques.

“We are delighted to announce the filing of this patent,” David Smith, CEO of IQ-AI’s operating subsidiaries, said in a prepared statement. “We believe the potential exists to develop, for the first time, a contrast agent-free imaging technology that should generate output comparable to traditional contrast-based imaging, offering significant savings to global healthcare systems. We now intend to develop the technology and conduct the clinical work necessary to prepare for worldwide regulatory submissions.”

The software was developed by Elm Grove, Wisconsin-based Imaging Biometrics, which was then acquired by IQ-AI in May 2018.

For more Radiology Business coverage of GBCAs, including more recent controversies surrounding potential gadolinium retention in the brain, click here and here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Practice managers demand ‘immediate action’ on physician Medicare pay cut
Interventional radiologists across the globe agree: Specialty must increase awareness
Payment incentives fail to push physicians toward MRI surveillance of low-risk prostate cancer
Radiologists can play key role in radiation therapy planning, but reimbursement an impediment
4 solutions to the biggest challenges facing remote radiologists
Imaging leaders share 7 key considerations for remote scanning programs

Around the web

Health Imaging
Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.